Brief: Cspc Pharmaceutical Says Sys6010 Meets Primary Endpoint Of Progression-Free Survival In Phase Iii Synstar-01 Study
26/08/2026 11:32
BRIEF-Cspc Pharmaceutical Says Sys6010 Meets Primary Endpoint Of Progression-Free Survival In Phase Iii Synstar-01 Study Aug 26 (Reuters) - CSPC PHARMACEUTICAL 1093.HK:
SYS6010 MEETS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL IN PHASE III SYNSTAR-01 STUDY
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines